A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment
EG-70-101
Phase 2 other active
Quick answer
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients who are BCG Naïve or Received Incomplete BCG Treatment for Non-muscle invasive bladder cancer (NMIBC) is a Phase 2 program (other) at enGene Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- enGene Therapeutics
- Indication
- Non-muscle invasive bladder cancer (NMIBC)
- Phase
- Phase 2
- Modality
- other
- Status
- active